Stephanie A. Gregory

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Jonathan W. Friedberg, Jeff P. Sharman, John Sweetenham et al. · Blood · 2009 · 739 citations · Full text

Medicine, Oncology, Pharmacology +10

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

Philippe Armand, Arnon Nagler, Edie Weller et al. · Journal of Clinical Oncology · 2013 · 439 citations · Full text

Medicine, Hematology, Oncology +17

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia

Steven P. Treon, Andrew R. Branagan, Leukothea Ioakimidis et al. · Blood · 2008 · 147 citations · Full text

Life Sciences, Hematology, Immunology +8

Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma

Robert M. Rifkin, Stephanie A. Gregory, Ann Mohrbacher et al. · Cancer · 2006 · 132 citations

Medicine, Oncology, Pharmacology +13

Imbalanced Expression of the Glucocorticoid Receptor Isoforms in Cultured Lymphocytes from a Patient with Systemic Glucocorticoid Resistance and Chronic Lymphocytic Leukemia

Homayoun Shahidi, Alessandra Vottero, Constantine A. Stratakis et al. · Biochemical and Biophysical Research Communications · 1999 · 118 citations

Life Sciences, Endocrinology, Immunology +12